Epic Sciences

Press Releases

10.13.2017

Liquid biopsy test identifies androgen receptor protein expression in circulating tumor cells in women with metastatic breast cancer.

Epic Sciences along with researchers at the MD Anderson Cancer Center (MDA) have recently published their findings on androgen receptor (AR) protein expression in circulating tumor cells (CTCs) in patients with metastatic breast cancer in PLOS One. The publication, the most comprehensive today in characterizing the AR protein in CTCs of patients with breast cancer, identifies subclonal heterogeneity of AR protein.

09.06.2017

Liquid biopsy tumor heterogeneity test predicts resistance to targeted therapy in metastatic prostate cancer patients.

A blood test measuring the diversity of individual circulating tumor cells correlates with differential survival on chemotherapy vs. targeted hormone therapy in metastatic prostate cancer and offers potential to guide treatment choices in multiple solid tumor cancers.

05.08.2017

Epic Sciences and collaborators publish study on new blood test showing expression of PD-L1 on circulating cells is associated with worse outcomes in lung cancer patients not treated with PD-1 inhibitors.

Investigators from Yale, USC, UC San Diego, and Epic Sciences published findings in Cancer Epidemiology, Biomarkers & Prevention, showing that the presence of PD-L1 protein on circulating cells from newly diagnosed lung cancer patients is prognostic of poor survival when patients are treated with standard of care therapeutics not including PD-1 inhibitors.

04.28.2017

Epic Sciences announces completion of $40 million Series D financing.

Epic Sciences announced today that the company has completed a $40 million Series D financing led by Hermed Capital. Altos Capital Partners, Domain Associates, Genomic Health, Pagoda Investment, Reach Tone Limited, RMI Partners, Sabby Capital and VI Ventures also participated in the financing.

01.06.2017

Study from MSK and Epic Sciences shows only nuclear-localized AR-V7 Is predictive of therapy benefit for patients with metastatic prostate cancer.

Investigators from Memorial Sloan Kettering Cancer Center (MSK) and Epic Sciences published findings in European Urology, that only nuclear localization of AR-V7 protein in circulating tumor cells (CTCs) from metastatic castration resistant prostatE cancer (mCRPC) patient blood samples is predictive of therapeutic benefit.

11.16.2016

Epic Sciences validates single CTC sequencing, identifies clonal heterogeneity in metastatic cancer.

Epic Sciences, in collaboration with pharma co-authors, published an analytic validation of their sequencing assay in single circulating tumor cells (CTC) and demonstrated clinical feasibility in metastatic prostate cancer patients (mCRPC).

11.16.2016

Liquid biopsy biomarker identifies patients with improved response to PARP inhibition in metastatic castrate resistant prostate cancer.

Epic Sciences announced findings demonstrating a circulating tumor cell (CTC) biomarker can identify patients with metastatic castrate resistant prostate cancer (mCRPC) who are more likely to respond to treatment with a PARP inhibitor in combination with androgen receptor signaling inhibitors (ARSi) compared to those treated with ARSi alone (overall response rate of 93 percent vs. 22 percent).